Drug intelligence / Profile preview

IDQ-DerMap

Development stage: Preclinical
Lead developer: ArrayPatch
Modality: Small Molecules
Administration: Transdermal, Cutaneous

Overview

IDQ-DerMap is a transdermal microneedle patch being developed by ArrayPatch for the treatment of migraines. It utilizes the company's proprietary DerMap™ technology, which is a polymer-free microneedle platform designed to enhance the delivery of therapeutic agents through the skin. By penetrating the stratum corneum, the microneedles allow for the systemic delivery of the drug, potentially offering a faster onset of action and avoiding the gastrointestinal side effects and first-pass metabolism associated with oral medications. The product is currently in the development stage, targeting a significant unmet need in the migraine market.

Other names: IDQ-DerMap microneedle patch

Beyond the preview

Go deeper on IDQ-DerMap.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDQ-DerMap.

Explore the full profile